A Study of the Effects of BMS-919373 on Atrial Effective Refractory Period in Subjects With a Dual-Chamber Pacemaker

Trial Profile

A Study of the Effects of BMS-919373 on Atrial Effective Refractory Period in Subjects With a Dual-Chamber Pacemaker

Discontinued
Phase of Trial: Phase I

Latest Information Update: 17 Feb 2017

At a glance

  • Drugs BMS 919373 (Primary) ; Sotalol
  • Indications Atrial fibrillation
  • Focus Therapeutic Use
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 14 Feb 2017 Status changed from recruiting to discontinued.
    • 11 Feb 2016 Planned End Date changed from 1 Jan 2016 to 1 Oct 2016, as reported by ClinicalTrials.gov record.
    • 11 Feb 2016 Planned primary completion date changed from 1 Jan 2016 to 1 Oct 2016, as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top